Sepsis continues to be an important clinical and research problem within critical care, as highlighted in the most recent literature.
The Surviving Sepsis Campaign bundle was updated in 2018 [1] . It was emphasised that within 1 h of presentation with sepsis, clinicians should: measure lactate, obtain blood cultures, administer broad-spectrum antimicrobials, begin fluid resuscitation with 30 ml/kg crystalloids, and apply vasopressors in case of fluid refractory shock. It was recommended that this new sepsis 1-h bundle should be used systematically in emergency departments, wards, and ICUs to reduce the global burden of sepsis [1]. While the 1-h bundle is welcomed and reasonable from a patient perspective, the quality of evidence supporting some individual elements of the bundle is low. A group of international experts representing the European Society of Intensive Care Medicine and the Society of Critical Care Medicine recently highlighted research priorities in the recent Surviving Sepsis Campaign guideline [2]. The top-six research priorities were use of personalised medicine in sepsis, fluid resuscitation, rapid diagnostic tests, empirical antibiotic combination therapy, long-term outcomes, and predictors of organ dysfunction.
The burden of sepsis has been the subject of numerous studies the previous year. In a large German nationwide cohort study, more than one out of four patients admitted to hospital were diagnosed with infection, and infection and sepsis were important causes of hospital and intensive-care unit (ICU) admission and death [3] . In a European observational study, the proportion of patients with sepsis admitted to the ICU remained constant throughout a 10-year period between 2002 and 2012, but disease severity seemed to increase [4] . In a Chinese population-based study, the standardised sepsis-related mortality rate was 67 deaths per 100,000 population, corresponding to more than 1 million sepsis-related deaths in 2015 in China [5] . Despite these alarming numbers and despite an estimated 30 million cases of sepsis and 6 million sepsis-related deaths in the world each year, there seems to be a lack of awareness of sepsis in the public. In a survey of Irish adults, less than 30% were aware of sepsis; a considerably lower proportion compared to other medical conditions, including myocardial infarction, asthma, and breast cancer [6] .
Early identification and prediction of patients at risk of developing sepsis, including sepsis-associated adverse outcomes, are paramount and have been researched extensively. In a multicentre cohort study in emergency departments and ICUs in the UK, discrimination of leukocyte surface biomarkers was assessed [7] . Disappointingly, most of the assessed biomarkers performed poorly and had limited clinical predictive validity. Correspondingly, circulating biomarkers were found to discriminate poorly between patients with and without sepsis, and no combination of biomarkers performed better than CRP alone in a French multicentre cohort study [8] .
Despite sound biological plausibility for using intravenous immunoglobulin as adjuvant therapy in sepsis, i.e., altered immunoglobulin and B-lymphocyte homeostasis in sepsis, the quality of evidence for its use is very low with no firm evidence for benefit or harm [9, 10]. Accordingly, the authors requested that more research is needed prior to using intravenous immunoglobulins as adjuvant therapy in patients with sepsis [9, 10].
Another promising intervention which has failed to improve the outcome of patients with sepsis is polymyxin B hemoperfusion [11] . In a post hoc analysis of the EUPHRATES trial, patients with high endotoxin activity had a small, but uncertain, benefit from polymyxin B hemoperfusion [12] . However, as highlighted by an accompanying editorial, the validity and clinical implications of this finding are hypothesis-generating only [13] . Use of vasopressin analogues in distributive shock, including septic shock, has been assessed in several studies the previous year. In a conventional systematic review and meta-analysis, high-quality evidence suggested reduced risk of atrial fibrillation in patients treated with vasopressin and catecholamines, as compared to catecholamines alone [14] . In a Chinese randomised clinical trial of 617 patients with septic shock, no difference in mortality between patients receiving terlipressin versus norepinephrine was observed; however, patients in the terlipressin group experienced more serious adverse events [15] . In a recent individual patient data meta-analysis of four RCTs, the use of vasopressin in patients with septic shock reduced arrhythmias, on the expense of a small increase in the risk of digital ischemia compared to norepinephrine [16] .
Following the publication of the ADRENAL and APROCCHSS trials last year-which reported somewhat inconsistent results on the effect of corticosteroids in patients with sepsis-updated systematic reviews and meta-analysis were published [17, 18] . They showed that treatment with corticosteroids does not affect short-or long-term mortality, increases adverse events, but reduces the duration of shock, mechanical ventilation, and ICU admission.
Methodological challenges in septic shock trials have also been discussed in 2018. In a systematic review of septic shock trials, trials reporting statistically significant findings with high control group mortality rates were more likely to be published (publication bias), and there was evidence of significant unexplained heterogeneity in the control groups [19, 20] . This should be considered when findings from sepsis trials are discussed and interpreted in the critical care community.
In summary, the body of evidence in sepsis research continues to grow, and Fig. 1 illustrates the recent dramatic increase in the number of clinical sepsis papers published. 
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